|
Re: Looking forward~~~
Sheila,
I know you will be interested in this article and I certainly hope you are receiving positive results with this drug. I think of you often and pray for your return to NED.
Your neck node BC sister, Nancy
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study
The Lancet - Early Online Publication, 03/04/2011
Cortes J et al. – The authors aimed to compare overall survival of heavily pretreated patients receiving eribulin versus currently available treatments. Eribulin showed a significant and clinically meaningful improvement in overall survival compared with TPC in women with heavily pretreated metastatic breast cancer. This finding challenges the notion that improved overall survival is an unrealistic expectation during evaluation of new anticancer therapies in the refractory setting
|